Baxter International (BAX)
(Real Time Quote from BATS)
$38.72 USD
-0.65 (-1.65%)
Updated Sep 19, 2024 01:08 PM ET
2-Buy of 5 2
A Value F Growth F Momentum D VGM
Average Brokerage Rating
Current ABR | 2.62 |
ABR (Last week) | 2.62 |
# of Recs in ABR | 14 |
Average Target Price | $41.77 |
LT Growth Rate | 10.00% |
Industry | Medical - Products |
Industry Rank by ABR | 65 of 253 |
Current Quarter EPS Est: | 0.78 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 10 | 10 | 10 | 10 | 11 |
Sell | 1 | 1 | 1 | 1 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.62 | 2.62 | 2.62 | 2.62 | 2.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Hold | Hold |
8/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/5/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/10/2024 | Not Identified | Not Identified | Hold | Hold |
7/2/2024 | Evercore Partners | Vijay Kumar | Strong Buy | Strong Buy |
5/30/2024 | Goldman Sachs | David H Roman | Not Available | Hold |
5/10/2024 | Cowen & Co. | Joshua T Jennings | Strong Buy | Hold |
5/3/2024 | Not Identified | Not Identified | Hold | Hold |
2/8/2024 | UBS | Research Department | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.